Physician profile
Katie E Queen
NPI 1952545972
$60,716.79
in general payments reported to CMS, 2019-2025
11 companies · $23K in 2025
The $23K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2021: $160 · 2022: $119 · 2023: $9,493 · 2024: $28K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Honoraria: $19K · Consulting Fee: $15K · Travel and Lodging: $4,171 · Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,281.40 |
| Honoraria | $19,468.58 |
| Consulting Fee | $14,757.75 |
| Travel and Lodging | $4,171.17 |
| Food and Beverage | $1,658.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $29,836.42 | 2022-2025 | Wegovy |
| Rhythm Pharmaceuticals, INC. | $25,019.99 | 2022-2025 | Imcivree, Imcivree |
| Otsuka America Pharmaceutical, INC. | $5,459.87 | 2024-2025 | |
| Glaxosmithkline, LLC. | $125.00 | 2021 | |
| Sanofi Pasteur INC. | $123.95 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $48.07 | 2022-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Regeneron Healthcare Solutions, INC. | $34.75 | 2025 | Dupixent |
| Soleno Therapeutics, INC. | $21.17 | 2025 | Vykat Xr |
| Lilly USA, LLC | $20.21 | 2024 | Zepbound |
| Pfizer INC. | $16.37 | 2024 | |
| Vapotherm INC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Queen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.